Literature DB >> 6224839

Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery.

J S Douglas, A R Gruentzig, S B King, J Hollman, T Ischinger, B Meier, J M Craver, E L Jones, J L Waller, D K Bone, R Guyton.   

Abstract

To improve symptomatic status and avoid reoperation, 122 initial and 7 repeat percutaneous transluminal coronary angioplasty procedures were performed in 116 patients with disabling angina pectoris at a mean of 26.8 months (range 2 to 132) after coronary bypass surgery. Marked angiographic improvement (greater than 30% reduction in diameter stenosis) was obtained in 107 (88%) of the 122 initial procedures and in all 7 repetitions. Mean stenosis was reduced from 78 +/- 13% (mean +/- standard deviation) to 25 +/- 13% (p less than 0.0001) and mean pressure gradient from 49 +/- 15 to 11 +/- 8 mm Hg (p less than 0.0001). Complications were: emergency surgery (three patients), Q wave infarction (one patient), myocardial infarction by enzyme criteria only (four patients) and non-occluding coronary dissection (one patient). There were no neurologic or peripheral vascular complications and no early deaths. One late death occurred 14 months after an unsuccessful but uncomplicated angioplasty procedure. At a mean follow-up of 8.3 months, 88 patients (76%) were free of angina or in improved condition. In patients followed up for at least 6 months, evidence of restenosis occurred in 9 (53%) of 17 saphenous veins, 1 (50%) of 2 proximal graft anastomoses, 4 (18%) of 22 distal graft anastomoses and 5 (14%) of 37 native coronary arteries. When coronary anatomy is suitable, percutaneous transluminal angioplasty is an attractive alternative to reoperation in symptomatic patients with prior coronary bypass surgery.

Entities:  

Mesh:

Year:  1983        PMID: 6224839     DOI: 10.1016/s0735-1097(83)80315-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis.

Authors:  Takahiro Uchida; Ameet Bakhai; Alexandra Almonacid; Taro Shibata; Barbra Cox; Richard E Kuntz
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

Review 2.  Percutaneous transluminal coronary angioplasty: state of the art and future directions.

Authors:  G S Roubin; A R Gruentzig
Journal:  Int J Card Imaging       Date:  1985

3.  Rupture of a saphenous vein bypass graft during coronary angioplasty.

Authors:  E Drummer; K Furey; J Hollman
Journal:  Br Heart J       Date:  1987-07

4.  Percutaneous coronary angioplasty: technique, indications, and results.

Authors:  G S Roubin; A R Gruentzig; W J Casarella
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

5.  Initial and subsequent angiographic outcome of percutaneous transluminal angioplasty performed on internal mammary artery grafts.

Authors:  N Ishizaka; Y Ishizaka; Y Ikari; T Isshiki; T Tamura; H Suma; T Yamaguchi
Journal:  Br Heart J       Date:  1995-12

Review 6.  Therapeutic strategies to combat neointimal hyperplasia in vascular grafts.

Authors:  Michael J Collins; Xin Li; Wei Lv; Chenzi Yang; Clinton D Protack; Akihito Muto; Caroline C Jadlowiec; Chang Shu; Alan Dardik
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-05

7.  Risk factors for the development of restenosis following stent implantation of venous bypass grafts.

Authors:  U E Heidland; M P Heintzen; C J Michel; B E Strauer
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

Review 8.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

9.  Clinical and angiographic acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary beta brachytherapy (RENO).

Authors:  T M Schiele; E Regar; S Silber; E Eeckhout; D Baumgart; W Wijns; A Colombo; W Rutsch; D Meerkin; A Gershlick; R Bonan; P Urban
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.